Exhibit 99.1

Contact:

Eric Slusser, Chief Financial Officer

Ben Bier, Vice President, Investor Relations

(314) 810-3115

investor.relations@express-scripts.com

Express Scripts Announces 2016 Second Quarter Results;

Narrows 2016 Full-Year Adjusted Diluted EPS Guidance Range; Raises Mid-Point;

Provides 2016 Third Quarter Guidance

ST. LOUIS, July 25, 2016 — Express Scripts Holding Company (Nasdaq: ESRX) announced 2016 second quarter net income of $720.7 million, or $1.13 per diluted share. 2016 second quarter adjusted earnings per diluted share, as detailed in Table 4, was $1.57.¹

“As the healthcare industry changes, a primary need of payers and patients remains the same: access to affordable medicine,” said Tim Wentworth, CEO and President. “An increase in our expected 2017 retention rate to a range of 96% to 98% is a direct result of our unique business model of client alignment, the industry’s most focused and innovative solutions, and a compassionate culture of caring employees.”

Second Quarter 2016 Review

The following compares second quarter 2016 and 2015 operating results:

As expected, revenue and operating income of $106.6 million related to a large client contract was realized in the second quarter of 2016 compared to $141.7 million in the second quarter of 2015 due to the structure of the contract.

In July 2016, the Company issued senior notes consisting of: $1,000.0 million aggregate principal amount of 3.000% senior notes due July 2023, $1,500.0 million aggregate principal amount of 3.400% senior notes due March 2027 and $1,500.0 million aggregate principal amount of 4.800% senior notes due July 2046. The Company used a portion of the net proceeds to repay a portion of its 2015 two-year term loan, to complete a tender offer for its 2.650% senior notes due 2017 and to complete a tender offer for a portion of each of the 7.125% senior notes due 2018 issued by Medco Health Solutions, Inc., the 7.250% senior notes due 2019 issued by Express Scripts, Inc. and the Company’s 6.125% senior notes due 2041. Total cash payments related to the above, excluding accrued interest, were $3,519.3 million, which included $132.0 million of repayment costs. During the remainder of the third quarter, the Company intends to use the remaining net proceeds to redeem the remaining aggregate principal amount of 2.650% senior notes due 2017, to complete the final settlement for the tender offer of the 7.125% senior notes due 2018 and for general corporate purposes.

2016 Guidance

The Company narrowed 2016 adjusted earnings per diluted share guidance from a range of $6.31 to $6.43 to a range of $6.33 to $6.43, which raises the mid-point from $6.37 to $6.38. The increased adjusted earnings per diluted share guidance range represents growth of 14% to 16% over 2015. Additional details on this guidance can be found in Table 6 including items excluded from this range.

The following table compares the current 2016 guidance to previous 2016 guidance:

The Company expects the following for the third quarter of 2016:

2016 Business Outlook

The Company is increasing its expected 2017 retention rate for the 2016 selling season to a range of 96% - 98%, excluding the impact of the remaining Coventry business rolling off in 2017, representing approximately 1% of claims.

About Express Scripts

Express Scripts puts medicine within reach of tens of millions of people by aligning with plan sponsors, taking bold action and delivering patient-centered care to make better health more affordable and accessible.

Headquartered in St. Louis, Express Scripts provides integrated pharmacy benefit management services, including network-pharmacy claims processing, home delivery pharmacy care, specialty pharmacy care, specialty benefit management, benefit-design consultation, drug utilization review, formulary management, and medical and drug data analysis services. Express Scripts also distributes a full range of biopharmaceutical products and provides extensive cost-management and patient-care services.

For more information, visit Lab.Express-Scripts.com or follow @ExpressScripts on Twitter.

SAFE HARBOR STATEMENT

This press release contains forward-looking statements, including, but not limited to, our 2016 guidance and our statements related to the Company’s plans, objectives, expectations (financial and otherwise) or intentions. Actual results may differ materially from those projected or suggested in any forward-looking statements. Factors that may impact these forward-looking statements can be found in Management’s Discussion and Analysis of Financial Condition and Results of Operations and Item 1A – “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the SEC on February 16, 2016. A copy of this document can be found at the Investor Information section of Express Scripts’ web site at http://www.express-scripts.com/corporate.

We do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

EXPRESS SCRIPTS HOLDING COMPANY

Unaudited Consolidated Statement of Operations

EXPRESS SCRIPTS HOLDING COMPANY

Unaudited Consolidated Balance Sheet

EXPRESS SCRIPTS HOLDING COMPANY

Unaudited Consolidated Statement of Cash Flows

Table 1

Express Scripts Holding Company Unaudited Consolidated Selected Information

(in millions)

Note: See Appendix for Footnotes

Table 2

Express Scripts Holding Company Unaudited Adjusted Gross Profit and Adjusted SG&A Reconciliation

Provided below are reconciliations of Adjusted gross profit and Adjusted selling, general and administrative expenses, which are non-GAAP measures, to Gross profit and Selling, general and administrative expenses, respectively, which are their most directly comparable measures calculated in accordance with U.S. GAAP.

(in millions)

Note: See Appendix for Footnotes

The Company is providing adjusted gross profit and adjusted selling, general and administrative expenses excluding the impact of transaction, integration and certain other costs and amortization of intangible assets (which are non-GAAP financial measures) in order to compare the underlying financial performance to prior periods.

Table 3

Express Scripts Holding Company Unaudited EBITDA and Adjusted EBITDA Reconciliation

(in millions, except per claim data)

Provided below is a reconciliation of EBITDA and Adjusted EBITDA attributable to Express Scripts to net income attributable to Express Scripts. The Company believes net income is the most directly comparable measure under U.S. GAAP.

Note: See Appendix for Footnotes

The Company is providing EBITDA and adjusted EBITDA excluding the impact of certain charges (both of which are non-GAAP financial measures) in order to compare the underlying financial performance to prior periods.

EBITDA attributable to Express Scripts is net income before provision for income taxes, depreciation and amortization and other expense. EBITDA attributable to Express Scripts is presented because it is a widely accepted indicator of a company’s ability to service indebtedness and is frequently used to evaluate a company’s performance. EBITDA attributable to Express Scripts, however, should not be considered as an alternative to net income, as a measure of operating performance, as an alternative to cash flow, as a measure of liquidity or as a substitute for any other measure computed in accordance with accounting principles generally accepted in the United States. In addition, our definition and calculation of EBITDA attributable to Express Scripts may not be comparable to that used by other companies.

Adjusted EBITDA attributable to Express Scripts is a supplemental measurement used by analysts and investors to help evaluate overall operating performance. Adjusted EBITDA attributable to Express Scripts is calculated excluding transaction and integration costs recorded each year and a legal settlement as these charges are not considered an indicator of ongoing company performance.

EBITDA and Adjusted EBITDA attributable to Express Scripts per adjusted claim is calculated by dividing EBITDA and Adjusted EBITDA, as applicable, by the adjusted claim volume for the period. This measure is used as an indicator of EBITDA and Adjusted EBITDA, as applicable, attributable to Express Scripts performance on a per unit basis. EBITDA and Adjusted EBITDA, as applicable, attributable to Express Scripts, and, as a result, EBITDA and Adjusted EBITDA, as applicable, attributable to Express Scripts per adjusted claim, are each affected by the changes in claims volume between retail and home delivery and the relative representation of brand-name, generic and specialty pharmacy drugs, as well as the level of efficiency in the business.

Table 4

Express Scripts Holding Company Unaudited Adjusted Diluted EPS Reconciliation

Provided below is a reconciliation of Adjusted diluted EPS attributable to Express Scripts, which is a non-GAAP measure, to Diluted

EPS attributable to Express Scripts, which is its most directly comparable measure calculated in accordance with U.S. GAAP.

Note: See Appendix for Footnotes

The Company is providing diluted EPS attributable to Express Scripts and adjusted diluted EPS attributable to Express Scripts excluding the impact of transaction, integration and certain other costs and amortization of intangible assets (which are non-GAAP financial measures) in order to compare the underlying financial performance to prior periods.

Table 5

Express Scripts Holding Company Unaudited Adjusted Net Income and Adjusted Effective Income Tax Rate Reconciliation

Provided below are reconciliations of Income before income taxes attributable to Express Scripts, as adjusted, and Adjusted net income attributable to Express Scripts, which are non-GAAP measures, to Income before income taxes, which is the most directly comparable measure calculated in accordance with U.S. GAAP.

(in millions)

Note: See Appendix for Footnotes

The Company is providing adjusted net income attributable to Express Scripts, net of tax and adjusted effective income tax rate attributable to Express Scripts excluding the impact of certain costs and amortization of intangible assets (which are non-GAAP financial measures) in order to compare the underlying financial performance to prior periods.

Table 5A

Express Scripts Holding Company Unaudited Adjusted Net Income and Adjusted Effective Income Tax Rate Reconciliation

Provided below are reconciliations of Income before income taxes attributable to Express Scripts, as adjusted, and Adjusted net income attributable to Express Scripts, which are non-GAAP measures, to Income before income taxes, which is the most directly comparable measure calculated in accordance with U.S. GAAP.

(in millions)

Note: See Appendix for Footnotes

The Company is providing adjusted net income attributable to Express Scripts, net of tax and adjusted effective income tax rate attributable to Express Scripts excluding the impact of transaction, integration and certain other costs and amortization of intangible assets (which are non-GAAP financial measures) in order to compare the underlying financial performance to prior periods.

Table 6

Express Scripts Holding Company Unaudited 2016 Guidance Information

Appendix

Footnotes

Amortization of legacy Express Scripts, Inc. (“ESI”) intangible assets include amounts in both revenues and selling, general and administrative expense.

Revenue amortization is related to the customer contract with Anthem which commenced upon closing of the NextRx acquisition in 2009. Amortization of intangibles that arises in connection with consideration given to a customer by a vendor is characterized as a reduction of revenues. Intangible amortization of $55.4 million ($34.8 million net of tax) and $23.8 million ($14.8 million net of tax) is included as a reduction to revenue for the three months ended June 30, 2016 and 2015, respectively. Intangible amortization of $89.7 million ($56.4 million net of tax) and $47.6 million ($29.7 million net of tax) is included as a reduction to revenue for the six months ended June 30, 2016 and 2015, respectively. The Company’s 10-year agreement with Anthem under which we provide pharmacy benefit management services to Anthem and its designated affiliates was previously amortized using a modified pattern of benefit method over an estimated useful life of 15 years. Beginning in March 2016, we began amortizing our agreement with Anthem over the remaining term of the contract (i.e. using a modified pattern of benefit over an estimated useful life of 10 years from the time the agreement was executed in 2009), which resulted in an additional $31.7 million of revenue amortization recognized for the three months ended June 30, 2016 and $42.2 million of revenue amortization recognized for the six months ended June 30, 2016.

Other legacy ESI intangible amortization of $9.5 million ($6.0 million net of tax) and $9.4 million ($5.9 million net of tax) for the three months ended June 30, 2016 and 2015, is included in selling, general and administrative expense. Other legacy ESI intangible amortization of $18.9 million ($11.9 million net of tax) and $18.8 million ($11.8 million net of tax) for the six months ended June 30, 2016 and 2015, is included in selling, general and administrative expense.

Amortization of intangible assets related to the acquisition of Medco of $398.8 million ($251.0 million net of tax) and $399.5 million ($248.9 million net of tax) for the three months ended June 30, 2016 and 2015, is included in selling, general and administrative expense, respectively. Amortization of intangible assets related to the acquisition of Medco of $798.4 million ($502.4 million net of tax) and $799.1 million ($498.6 million net of tax) for the six months ended June 30, 2016 and 2015, is included in selling, general and administrative expense, respectively.

Appendix

Footnotes

Costs of $40.7 million ($25.3 million net of tax) are primarily composed of integration-related activities, and are included in gross profit for the three months ended June 30, 2015. Costs of $95.4 million ($59.5 million net of tax) are primarily composed of integration-related activities, and are included in gross profit for the six months ended June 30, 2015.

Costs of $88.1 million ($55.0 million net of tax) are primarily composed of professional fees, integration-related activities and severance costs, and are included in selling, general and administrative expense for the three months ended June 30, 2015. Costs of $129.0 million ($80.5 million net of tax) are primarily composed of professional fees, integration-related activities and severance costs, and are included in selling, general and administrative expense for the six months ended June 30, 2015.